87 research outputs found
Policies for African seed enterprise development
The commercial seed sector has been slow to develop in sub-Saharan Africa. The paper examines the major impediments and identifies areas in which seed policies can be strengthened. Seed enterprise development has been hampered by regulatory frameworks that favor parastatal enterprises and that inhibit commercial innovation. In addition, government and donor projects provide large amounts of free or subsidized seed that further discourages seed enterprise development. In addition to regulatory reform and the curtailment of many seed distribution projects, there are other policy changes that need to be implemented. National agricultural research institutes need to invest more resources in promoting their varieties and helping to stimulate commercial seed production. Greater emphasis is required on regional strategies for public plant breeding and private seed marketing. National policies need to strengthen input marketing capacity and infrastructure. Finally, donors, governments and NGOs should shift from trying to encourage village-level commercial seed production and instead strengthen farmersβ capacities to assess new varieties and to be effective consumers of commercial input
The role of informal seed systems in disseminating modern varieties: example of pigeon pea in semi-arid area of Kenya
In the semi-arid Mwea Division of Kenya's Eastern Province, the modern pigeonpea (Cajanus cajan) variety Nairobi Pigeonpea 670 (NPP 670) had become known to all farmers and was being grown by 68% of them within a period of 12 years. The only injection of this seed to the area was from a single on-farm demonstration. Three-quarters of farmers found out about the variety from observing it growing in the field, and obtained seed primarily from other farmers in the village. Factors favouring the diffusion of the variety included its attractiveness as a cash crop, the ease with which it could be distinguished from other varieties, the low seed rate, and the relative ease with which growers were able to maintain seed purity. Farmers expressed a willingness to pay for fresh seed, which suggests that more effort needs to be made to involve the formal seed sector. The present regulatory system does not favour the development of a formal supply system. NPP 670 was released more than 10 years after it was first teste
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
PURPOSE: Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. METHODS: We used next-generation sequencing to study 214 patients with SMM. We performed whole-exome sequencing on 166 tumors, including 5 with serial samples, and deep targeted sequencing on 48 tumors. RESULTS: We observed that most of the genetic alterations necessary for progression have already been acquired by the diagnosis of SMM. Particularly, we found that alterations of the mitogen-activated protein kinase pathway (KRAS and NRAS single nucleotide variants [SNVs]), the DNA repair pathway (deletion 17p, TP53, and ATM SNVs), and MYC (translocations or copy number variations) were all independent risk factors of progression after accounting for clinical risk staging. We validated these findings in an external SMM cohort by showing that patients who have any of these three features have a higher risk of progressing to MM. Moreover, APOBEC associated mutations were enriched in patients who progressed and were associated with a shorter time to progression in our cohort. CONCLUSION: SMM is a genetically mature entity whereby most driver genetic alterations have already occurred, which suggests the existence of a right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM. We identified and externally validated genomic predictors of progression that could distinguish patients at high risk of progression to MM and, thus, improve on the precision of current clinical models
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
BACKGROUND: Patients with precursors to multiple myeloma are dichotomised as having monoclonal gammopathy of undetermined significance or smouldering multiple myeloma on the basis of monoclonal protein concentrations or bone marrow plasma cell percentage. Current risk stratifications use laboratory measurements at diagnosis and do not incorporate time-varying biomarkers. Our goal was to develop a monoclonal gammopathy of undetermined significance and smouldering multiple myeloma stratification algorithm that utilised accessible, time-varying biomarkers to model risk of progression to multiple myeloma. METHODS: In this retrospective, multicohort study, we included patients who were 18 years or older with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma. We evaluated several modelling approaches for predicting disease progression to multiple myeloma using a training cohort (with patients at Dana-Farber Cancer Institute, Boston, MA, USA; annotated from Nov, 13, 2019, to April, 13, 2022). We created the PANGEA models, which used data on biomarkers (monoclonal protein concentration, free light chain ratio, age, creatinine concentration, and bone marrow plasma cell percentage) and haemoglobin trajectories from medical records to predict progression from precursor disease to multiple myeloma. The models were validated in two independent validation cohorts from National and Kapodistrian University of Athens (Athens, Greece; from Jan 26, 2020, to Feb 7, 2022; validation cohort 1), University College London (London, UK; from June 9, 2020, to April 10, 2022; validation cohort 1), and Registry of Monoclonal Gammopathies (Czech Republic, Czech Republic; Jan 5, 2004, to March 10, 2022; validation cohort 2). We compared the PANGEA models (with bone marrow [BM] data and without bone marrow [no BM] data) to current criteria (International Myeloma Working Group [IMWG] monoclonal gammopathy of undetermined significance and 20/2/20 smouldering multiple myeloma risk criteria). FINDINGS: We included 6441 patients, 4931 (77%) with monoclonal gammopathy of undetermined significance and 1510 (23%) with smouldering multiple myeloma. 3430 (53%) of 6441 participants were female. The PANGEA model (BM) improved prediction of progression from smouldering multiple myeloma to multiple myeloma compared with the 20/2/20 model, with a C-statistic increase from 0Β·533 (0Β·480-0Β·709) to 0Β·756 (0Β·629-0Β·785) at patient visit 1 to the clinic, 0Β·613 (0Β·504-0Β·704) to 0Β·720 (0Β·592-0Β·775) at visit 2, and 0Β·637 (0Β·386-0Β·841) to 0Β·756 (0Β·547-0Β·830) at visit three in validation cohort 1. The PANGEA model (no BM) improved prediction of smouldering multiple myeloma progression to multiple myeloma compared with the 20/2/20 model with a C-statistic increase from 0Β·534 (0Β·501-0Β·672) to 0Β·692 (0Β·614-0Β·736) at visit 1, 0Β·573 (0Β·518-0Β·647) to 0Β·693 (0Β·605-0Β·734) at visit 2, and 0Β·560 (0Β·497-0Β·645) to 0Β·692 (0Β·570-0Β·708) at visit 3 in validation cohort 1. The PANGEA models improved prediction of monoclonal gammopathy of undetermined significance progression to multiple myeloma compared with the IMWG rolling model at visit 1 in validation cohort 2, with C-statistics increases from 0Β·640 (0Β·518-0Β·718) to 0Β·729 (0Β·643-0Β·941) for the PANGEA model (BM) and 0Β·670 (0Β·523-0Β·729) to 0Β·879 (0Β·586-0Β·938) for the PANGEA model (no BM). INTERPRETATION: Use of the PANGEA models in clinical practice will allow patients with precursor disease to receive more accurate measures of their risk of progression to multiple myeloma, thus prompting for more appropriate treatment strategies. FUNDING: SU2C Dream Team and Cancer Research UK
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
Background: Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response [residual cancer burden (RCB)-0/1] to single-agent cisplatin or paclitaxel. Patients and methods: This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage IβIII TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score β₯33. Crossover to an alternative chemotherapy was offered if there was inadequate response. Results: One hundred and thirty-nine patients were evaluable for response, including 88 (63.3%) who had surgery at 12 weeks and 51 (36.7%) who crossed over to an alternative provider-selected preoperative chemotherapy regimen due to inadequate clinical response. HRD results were available for 104 tumors (74.8%) and 74 (71.1%) were HRD positive. The RCB-0/1 rate was 26.4% with cisplatin and 22.3% with paclitaxel. No significant association was observed between HRD score and RCB response to either cisplatin [odds ratio (OR) for RCB-0/1 if HRD positive 2.22 (95% CI: 0.39β23.68)] or paclitaxel [OR for RCB-0/1 if HRD positive 0.90 (95% CI: 0.19β4.95)]. There was no evidence of an interaction between HRD and pathologic response to chemotherapy. Conclusions: In this prospective preoperative trial in TNBC, HRD was not predictive of pathologic response. Tumors were similarly responsive to preoperative paclitaxel or cisplatin chemotherapy
ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΉ ΠΌΡΠ·ΡΠΊΠ°Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½ΠΊΡΡΡ Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ (Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ 2017)
ΠΠ½Π½ΠΎΡΠ°ΡΠΈΡ Π²ΡΠΏΡΡΠΊΠ½ΠΎΠΉ ΠΊΠ²Π°Π»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΠΡΠ»ΠΎΠ² ΠΠΈΠΊΠΈΡΠ° Π‘Π΅ΡΠ³Π΅Π΅Π²ΠΈΡ Β«ΠΠΠΠΠ£ΠΠΠ ΠΠΠΠ«Π ΠΠ£ΠΠ«ΠΠΠΠ¬ΠΠ«Π ΠΠΠΠΠ£Π Π‘ Π Π€ΠΠ ΠΠΠ ΠΠΠΠΠΠ ΠΠΠΠΠΠ Π‘Π’Π ΠΠΠ« ΠΠ ΠΠΠΠΠΠΠΠ― (ΠΠ ΠΠ ΠΠΠΠ Π ΠΠΠ ΠΠΠΠΠΠΠΠ―-2017)Β» Π. ΡΡΠΊ. - ΠΡΠΊΠΎΠ²Π° ΠΠ»Π΅Π½Π° ΠΠ»Π°Π΄ΠΈΠΌΠΈΡΠΎΠ²Π½Π°, Π΄ΠΎΠΊΡΠΎΡ ΡΠΈΠ»ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°ΡΠΊ, Π΄ΠΎΡΠ΅Π½Ρ ΠΠ°ΡΠ΅Π΄ΡΠ° ΡΠ²ΡΠ·Π΅ΠΉ Ρ ΠΎΠ±ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΡΡΡΡ ΠΡΠ½Π°Ρ ΡΠΎΡΠΌΠ° ΠΎΠ±ΡΡΠ΅Π½ΠΈΡ ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ: ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΉ ΠΌΡΠ·ΡΠΊΠ°Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½ΠΊΡΡΡ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊ ΡΠ°ΠΌΠΎΠ΅ ΠΌΠ°ΡΡΡΠ°Π±Π½ΠΎΠ΅ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎΠ΅ Π²ΡΡΠΎΠΊΠΎΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΠΎΠ΅ ΡΠ΅Π»Π΅Π²ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠ΅ ΠΈ ΠΌΠ΅Π΄ΠΈΠ°-ΡΠΎΠ±ΡΡΠΈΠ΅, ΠΊΠΎΡΠΎΡΠΎΠ΅ . Π Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΠΎ Π°ΠΊΡΠ΅Π½ΡΠΈΡΡΠ΅Ρ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π°ΡΠ΄ΠΈΡΠΎΡΠΈΠΈ Π½Π° Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ-ΠΊΡΠ»ΡΡΡΡΠ½ΡΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
ΡΡΡΠ°Π½Ρ-ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΎΡΠ° ΠΊΠΎΠ½ΠΊΡΡΡΠ°, ΡΠΎΡΠΌΠΈΡΡΠ΅Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΡΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΡΠΎΠΊΠΈ ΠΈ ΡΠ΅ΠΌ ΡΠ°ΠΌΡΠΌ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ. ΠΠΎΠ»Π΅Π΅ ΡΠΎΠ³ΠΎ, ΠΏΠΎΠ±Π΅Π΄Π° ΡΡΡΠ°Π½Ρ-ΡΡΠ°ΡΡΠ½ΠΈΡΡ ΠΊΠΎΠ½ΠΊΡΡΡΠ° ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ Π·Π°ΡΠ°ΡΡΡΡ ΠΎΡΡΠ°ΠΆΠ°Π΅Ρ ΠΈΠ΄Π΅ΠΎΠ»ΠΎΠ³ΠΎ-ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π²Π΅ΠΊΡΠΎΡ ΠΠ²ΡΠΎΠΏΡ ΠΈ ΠΏΠΎ ΡΡΡΠΈ Π΄Π΅Π»Π° Π²ΡΠΏΠΎΠ»Π½ΡΠ΅Ρ ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ PR ΡΡΡΠ°Π½Ρ-ΠΏΠΎΠ±Π΅Π΄ΠΈΡΠ΅Π»Ρ ΠΈ ΡΡΡΠ°Π½Ρ-Ρ
ΠΎΠ·ΡΠΉΠΊΠΈ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΡ. Π‘Π»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎ Π°Π½Π°Π»ΠΈΠ· ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
Π½Π° ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΈ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ ΠΈ Π²ΠΎΡΡΡΠ΅Π±ΠΎΠ²Π°Π½Π½ΡΠΌ Π΄Π»Ρ ΡΠΎΠ±ΡΡΠΈΠΉΠ½ΠΎΠ³ΠΎ ΠΈ ΡΡΡΡΠΎΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ PR ΠΠ±ΡΠ΅ΠΊΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΌΡΠ·ΡΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΠΊΡΡΡΠ° (Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ Π² ΠΠΈΠ΅Π²Π΅ Π² 2017 Π³.). ΠΡΠ΅Π΄ΠΌΠ΅Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΡΡΠ½ΠΊΡΠΈΡ ΡΡΠ°ΡΡΡΠ½ΠΎΠ³ΠΎ PR-ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΡ Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: Π΄ΠΎΠΊΠ°Π·Π°ΡΡ, ΡΡΠΎ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΉ ΠΌΡΠ·ΡΠΊΠ°Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½ΠΊΡΡΡ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ. ΠΠ°Π΄Π°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°ΡΡ ΡΠ΅ΡΠΌΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΠΏΠΏΠ°ΡΠ°Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π½Π°ΡΡΠ½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΏΠΎ ΠΈΠΌΠΈΠ΄ΠΆΠΌΠ΅ΠΉΠΊΠΈΠ½Π³Ρ, Π±ΡΠ΅Π½Π΄ΠΈΠ½Π³Ρ ΠΈ ΠΈΠ²Π΅Π½Ρ-ΠΌΠ΅Π½Π΅Π΄ΠΆΠΌΠ΅Π½ΡΡ; ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΠ΅ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ Π΄Π»Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ; ΠΎΠΏΠΈΡΠ°ΡΡ ΡΠΎΠ»Ρ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠ³ΠΎ ΠΠ΅ΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π‘ΠΎΡΠ·Π° ΠΊΠ°ΠΊ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΎΡΠ° ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΊΠΎΠ½ΠΊΡΡΡΠ°; ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅Π°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ; Π΄Π°ΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ. Π’Π΅ΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π±Π°Π·Π°: Π½Π°ΡΡΠ½ΡΠ΅ ΡΡΡΠ΄Ρ Π. ΠΡΠΊΠΎΠ²ΠΎΠΉ, Π. ΠΠ°Π²ΡΡ, Π. ΠΠ°Π½ΠΊΡΡΡ
ΠΈΠ½Π°, Π. ΠΠΆΠ΅Π½Π΅ΡΠ°, Π. ΠΠ°Π²Π΅ΡΠΈΠ½ΠΎΠΉ, Π£. Π₯Π°Π»ΡΡΠ±Π°ΡΡΠ°, ΠΠΆ. ΠΠΎΠ»Π΄Π±Π»Π°ΡΡΠ° Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΡΠ΄Ρ Π. ΠΠ°ΡΡΠΌΠ°Π½Π° ΠΎ ΠΌΡΠ·ΡΠΊΠ°Π»ΡΠ½ΠΎΠΌ Π±ΠΈΠ·Π½Π΅ΡΠ΅, Π. ΠΠΆΠΎΡΠ΄Π°Π½Π° ΠΎ ΠΏΡΠΎΠ΄Π²ΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ ΠΈ Π΄Ρ. ΠΠΌΠΏΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π±Π°Π·Π°: PR-Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΡ, ΡΠ°Π·ΠΌΠ΅ΡΠ΅Π½Π½ΡΠ΅ Π½Π° ΡΠ°ΠΉΡΠ΅ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ ΠΈ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠ³ΠΎ ΠΠ΅ΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π‘ΠΎΡΠ·Π°; Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»ΡΡΠΎΡΠ° ΠΌΠΈΠ»Π»ΠΈΠΎΠ½Π° ΡΡΠ°ΡΠ΅ΠΉ ΠΎΠ± Π£ΠΊΡΠ°ΠΈΠ½Π΅ Π² Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΈΡ
Π‘ΠΠ, ΡΠ°Π·ΠΌΠ΅ΡΠ΅Π½Π½ΡΠ΅ Π² Π±Π°Π·Π΅ ΠΏΡΠΎΠ΅ΠΊΡΠ° ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠΌΠΈΠ΄ΠΆΠ° Π£ΠΊΡΠ°ΠΈΠ½Ρ Β«OkoΒ»; Π΄Π°Π½Π½ΡΠ΅ Π±Π°Π·Ρ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π‘ΠΠ ΠΈ ΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΌΠ΅Π΄ΠΈΠ° Factiva; Π΄Π°Π½Π½ΡΠ΅ Google.Analytics. ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π΄ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ, ΡΡΠΎ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΉ ΠΌΡΠ·ΡΠΊΠ°Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½ΠΊΡΡΡ ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ ΡΠΎΡΠΌΠΈΡΡΠ΅Ρ ΠΈΠΌΠΈΠ΄ΠΆ ΡΡΡΠ°Π½Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ ΡΡΠΏΠ΅ΡΠ½ΠΎΡΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½Ρ. Π’Π΅Π·ΠΈΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ Π°ΠΏΡΠΎΠ±ΠΈΡΠΎΠ²Π°Π½Ρ Π½Π° ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠΌ Π½Π°ΡΡΠ½ΠΎΠΌ ΡΠΎΡΡΠΌΠ΅ Β«ΠΠ΅Π΄ΠΈΠ° Π² ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΠΌΠΈΡΠ΅. 57-Π΅ ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³ΡΠΊΠΈΠ΅ ΡΡΠ΅Π½ΠΈΡΒ», ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Ρ Π² ΡΠ±ΠΎΡΠ½ΠΈΠΊΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΡΡΠ°ΡΠ΅ΠΉ ΡΠΎΡΡΠΌΠ° ΠΈ ΠΈΠΌΠ΅ΡΡ ΡΡΠ°ΡΡΡ Π½Π°ΡΡΠ½ΠΎΠΉ ΡΡΠ°ΡΡΠΈ, ΡΠ°Π·ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠΉ Π² Π±Π°Π·Π΅ Π ΠΠΠ¦. Π‘ΡΡΡΠΊΡΡΡΠ° ΡΠ°Π±ΠΎΡΡ: Π Π°Π±ΠΎΡΠ° ΡΠΎΡΡΠΎΠΈΡ ΠΈΠ· Π²Π²Π΅Π΄Π΅Π½ΠΈΡ, 3 Π³Π»Π°Π²: Β«ΡΡΠ½ΠΊΡΠΈΡ ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ±ΡΡΠΈΡ Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½ΡΒ», Β«ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊ ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ΅ ΡΠΎΠ±ΡΡΠΈΠ΅ ΠΠ²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠ³ΠΎ ΠΠ΅ΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π‘ΠΎΡΠ·Π°Β» ΠΈ Β«ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠΉ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π» ΠΠ²ΡΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΡ ΠΊΠ°ΠΊ ΠΏΠ»ΠΎΡΠ°Π΄ΠΊΠΈ Π΄Π»Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈΠΌΠΈΠ΄ΠΆΠ° ΡΡΡΠ°Π½ΡΒ», Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ, ΡΠΏΠΈΡΠΊΠ° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Π½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈΠ· 67 ΠΏΠΎΠ·ΠΈΡΠΈΠΉ ΠΈ 12 ΠΏΡΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ. ΠΠ±ΡΠΈΠΉ ΠΎΠ±ΡΠ΅ΠΌ 76 ΡΡΡΠ°Π½ΠΈΡ.Abstract of graduating qualification thesis Mikita Arlou INTERNATIONAL MUSIC CONTEST IN HOST COUNTRY IMAGE FORMATION (ON THE EXAMPLE OF EUROVISION 2017) Supervisor associate professor Elena Bykova, doctor of philology Department of PR in business full-time study Relevance: the international music contest Eurovision as the most wide scale regular high tech TV and Media event which annually emphasizes audience attention on national cultural features of the host country, forms tourist flows which have huge influence on territorial image formation. Besides the win of a participating in the Eurovision country often shows the ideological and political European vector and in fact serves as political PR of the winning or host country. Consequently the analysis of applied communication technologies is relevant and in-demand for event PR. Research object: communication activities of international music contest (on the example of Eurovision in Kyiv in 2017). Research subject: function of status PR event in country image formation. The aim of research: to prove that international music contest Eurovision contributes host country image formation. The tasks of research: to develop research terminology based on scientific literature on image making, branding and event management; to define actual communication technologies applied in special PR events on country image formation; to describe European Broadcasting Union role in host country image formation; to appreciate effectiveness of applied communication technologies on host country image formation in Eurovision; to give recommendations for host country image formation with the help of Eurovision. Theoretical base: scientific works written by E. Bykova, D. Gavra, A. Pankrukhin, B. Jenes, E. Kaverina, U. Halcbaur, J. Goldblatt and D. PassmanΒ΄s works on music business and P. Jordan on county image building with the help of Eurovision, etc. The empirical base: PR documents from official Eurovision and European Broadcasting Union websites; more than 1.5 million articles on Ukraine in European media stored in the base of international Ukrainian image monitoring project Oko; content of the mass media and social media base Factiva; Google.Analytics data. Practical significance: the research proves that international music contest Eurovision is relevant for the host country image formation independently of the success level of applied country image formation communication technologies. Approbation: General positions of current thesis were aprobated on international scientific forum Media in modern world and were published at the collection of articles of the forum and have the status of a scientific article posted in the RINC database. Thesis structure: Research consists of introduction, 3 chapters: Special event function in country image formation, Eurovision as EBU special event and communication potential of Eurovision as a platform for image formation; conclusion, literature list from 67 positions and 12 attachments. The total volume is 76 pages
Dynamics of phosphoglucomutase heat sensitivity polymorphism in Culicidae
[No abstract available
Hidden phosphoglucomutase (PGM) genetic polymorphism in a natural population of Culiseta litorea (Diptera, Culicidae).
[No abstract available
- β¦